FIELD: immunology.
SUBSTANCE: disclosed is a modified T-cell receptor which binds to a complex of peptide WT1 and molecules HLA-A2, and its antigen-binding fragment. Compositions are also described and used in preparing a drug for treating a subject having cancer.
EFFECT: this group of inventions can find application in therapy of WT1 related diseases.
10 cl, 12 dwg, 3 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
CONSTRUCTED HIGH-AFFINITY HUMAN T-CELL RECEPTORS | 2014 |
|
RU2729383C2 |
SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
VACCINE COMPOSITION FOR MALIGNANT TUMOR | 2013 |
|
RU2721574C2 |
HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
Authors
Dates
2021-01-19—Published
2014-11-21—Filed